Mabpharm Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Mabpharm's earnings have been declining at an average annual rate of -2%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 39.8% per year.
Belangrijke informatie
-2.0%
Groei van de winst
0.6%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 11.0% |
| Inkomstengroei | 39.8% |
| Rendement op eigen vermogen | -179.6% |
| Nettomarge | -136.5% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now
Jun 14
More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%
Jan 24Mabpharm (HKG:2181) Is Making Moderate Use Of Debt
Oct 20Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation
Jan 18Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation
Oct 07Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation
Apr 28Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?
Mar 03We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate
Jan 27
Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?
Dec 09Opbrengsten en kosten
Hoe Mabpharm geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 152 | -207 | 210 | 120 |
| 31 Mar 24 | 119 | -208 | 182 | 122 |
| 31 Dec 23 | 87 | -209 | 154 | 123 |
| 30 Sep 23 | 79 | -202 | 142 | 126 |
| 30 Jun 23 | 71 | -194 | 131 | 129 |
| 31 Mar 23 | 64 | -202 | 125 | 139 |
| 31 Dec 22 | 56 | -211 | 119 | 148 |
| 30 Sep 22 | 43 | -237 | 119 | 163 |
| 30 Jun 22 | 30 | -263 | 119 | 178 |
| 31 Mar 22 | 57 | -278 | 110 | 221 |
| 31 Dec 21 | 83 | -292 | 100 | 264 |
| 30 Sep 21 | 82 | -284 | 89 | 243 |
| 30 Jun 21 | 81 | -276 | 79 | 223 |
| 31 Mar 21 | 41 | -230 | 72 | 172 |
| 31 Dec 20 | 0 | -185 | 66 | 120 |
| 30 Sep 20 | 5 | -163 | 66 | 128 |
| 30 Jun 20 | 11 | -141 | 66 | 136 |
| 31 Mar 20 | 12 | -172 | 64 | 135 |
| 31 Dec 19 | 14 | -203 | 63 | 134 |
| 30 Sep 19 | 16 | -208 | 60 | 128 |
| 30 Jun 19 | 17 | -212 | 57 | 121 |
| 31 Mar 19 | 21 | -169 | 50 | 105 |
| 31 Dec 18 | 24 | -125 | 42 | 89 |
| 31 Dec 17 | 5 | -31 | 25 | 22 |
Kwaliteitswinsten: 2181 is currently unprofitable.
Groeiende winstmarge: 2181 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 2181 is unprofitable, and losses have increased over the past 5 years at a rate of 2% per year.
Versnelling van de groei: Unable to compare 2181's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 2181 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).
Rendement op eigen vermogen
Hoge ROE: 2181 has a negative Return on Equity (-179.64%), as it is currently unprofitable.